Pro-Dex (NASDAQ:PDEX) Issues Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Pro-Dex (NASDAQ:PDEX) released its earnings results on Thursday. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23, Zacks reports. Pro-Dex had a net margin of 9.17% and a return on equity of 16.74%.

Pro-Dex Trading Down 0.7 %

Shares of NASDAQ PDEX traded down $0.31 on Thursday, reaching $42.95. 31,928 shares of the company traded hands, compared to its average volume of 28,640. The stock has a market capitalization of $140.02 million, a PE ratio of 27.89 and a beta of 0.56. Pro-Dex has a fifty-two week low of $16.18 and a fifty-two week high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The company has a 50 day moving average of $47.59 and a 200 day moving average of $34.34.

Insider Buying and Selling

In other news, CFO Alisha Charlton sold 1,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $40.02, for a total value of $40,020.00. Following the transaction, the chief financial officer now directly owns 15,339 shares in the company, valued at $613,866.78. This trade represents a 6.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Raymond E. Cabillot sold 5,381 shares of Pro-Dex stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $41.64, for a total value of $224,064.84. Following the completion of the transaction, the director now directly owns 319,752 shares in the company, valued at $13,314,473.28. This represents a 1.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,670 shares of company stock valued at $1,229,821. Insiders own 47.50% of the company’s stock.

Analyst Ratings Changes

PDEX has been the subject of a number of analyst reports. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th. Ascendiant Capital Markets increased their price target on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.